On February 23, 2023 BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine reported a co-development arrangement with the J. Craig Venter Institute (JCVI), a world-leading institution in genomics research and innovation, for the design and validation of a synthetic HSV-1 (herpes simplex type 1) virus particle targeting colorectal cancer (Press release, Bullfrog AI, FEB 23, 2023, View Source [SID1234635367]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This project leverages our bfLEAP artificial intelligence and machine learning platform to optimize oncolytic HSV-1 particle design for cancer-cell-specific targeting, reduced toxicity, and therapeutic payload," said BullFrog AI’s founder and CEO, Vin Singh. "Our objective with this collaboration is to generate a novel class of targeted colorectal cancer therapeutics with potential for a best-in-class toxicity profile, while providing a clear demonstration of our ability to advance development of new medicines using artificial intelligence."
"The JCVI has been at the forefront of synthetic biology for more than 25 years, and we’ve long stated that the knowledge, tools, and techniques developed have broad use. It is gratifying seeing their application in such an impactful area of human health, and we look forward to working with BullFrog AI," remarked J. Craig Venter, Ph.D., chairman, CEO, and founder of JCVI.
"We are excited to partner with Bullfrog AI. The combination of artificial intelligence and engineered biology approaches has the potential to rapidly develop safer precision cancer therapeutics," added Sanjay Vashee, Ph.D., professor and director of the JCVI, Rockville, Maryland campus.
According to the American Cancer Society, colorectal cancer is the third most common cancer diagnosed in both men and women in the U.S., excluding skin cancers, and is the third leading cause of cancer-related deaths in the U.S.